Antibodies 孤立するd from Covid-19 患者s may 抑える ウイルス, 熟考する／考慮する 示唆するs
研究員s have 孤立するd antibodies from Covid-19 患者s which they say are の中で the most potent in neutralising coronavirus.
These antibodies could be produced in large 量s by 製薬の companies to 扱う／治療する 患者s, 特に 早期に in the course of 感染.
They can also be used to 妨げる 感染, 特に in the 年輩の, the scientists say.
The 熟考する／考慮する, published in Nature, 報告（する）／憶測s that 研究員s have 確認するd the purified, 堅固に neutralising antibodies 供給する 重要な 保護 from SARS-CoV-2 感染 in hamsters.
David 売春婦, 科学の director of the Aaron Diamond 援助（する）s 研究 Centre and professor of 薬／医学 at Columbia University Vagelos College of 内科医s and 外科医s, directed the 熟考する／考慮する.
He said: “We now have a collection of antibodies that’s more potent and diverse compared to other antibodies that have been 設立する so far, and they are ready to be developed into 治療s.”
Antibodies 孤立するd from Covid-19 患者s may 抑える the ウイルス, a 熟考する／考慮する 示唆するs (PA)
The 免疫の system’s 返答 to 感染 is to produce antibodies when it identifies 実体s in the 団体／死体 as 外国人, such as bacteria, ウイルスs, and foreign 実体s in the 血.
While a number of 麻薬s and ワクチンs in 開発 for Covid-19 are in 臨床の 裁判，公判s, they may not be ready for several months.
So the 研究員s say that in the 合間, SARS-CoV-2 neutralising antibodies produced by Covid-19 患者s could be used to 扱う／治療する other 患者s or even 妨げる 感染 in people exposed to the ウイルス.
The 開発 and 是認 of antibodies for use as a 治療 usually takes いっそう少なく time than 従来の 麻薬s.
The 熟考する／考慮する 設立する that in the 患者s they 熟考する／考慮するd, those with 厳しい 病気 要求するing mechanical ventilation produced the most potently neutralising antibodies.
Prof 売春婦 said: “We think that the sicker 患者s saw more ウイルス and for a longer period of time, which 許すd their 免疫の system to 開始する a more 強健な 返答.
“This is 類似の to what we have learned from the HIV experience.”
The 研究 team 設立する a more diverse variety of antibodies than previous 成果／努力s, 含むing new, unique antibodies that were not 報告（する）／憶測d earlier.
Prof 売春婦 said: “These findings show which 場所／位置s on the viral spike are most 攻撃を受けやすい.
“Using a cocktail of different antibodies that are directed to different 場所／位置s in spike will help 妨げる the ウイルス becoming 抵抗力のある to the 治療.
“We discovered that these powerful antibodies are not too difficult for the 免疫の system to 生成する. This bodes 井戸／弁護士席 for ワクチン 開発.
“ワクチンs that elicit strong neutralising antibodies should 供給する 強健な 保護 against the ウイルス.”
The scientists say their 研究 示唆するs people with 厳しい 病気 are more likely to have a 持続する antibody 返答, however more 研究 needs to be done to answer the 批判的な question about how long 免疫 will last.
But they 警告を与える that although informative for 研究員s developing ワクチンs and antiviral therapies, the findings are 早期に-行う／開催する／段階 preclinical results and the antibodies are not yet ready for use in people.
Forty 患者s who had 実験（する）d 肯定的な for coronavirus were 入会させるd in a cohort 熟考する／考慮する on ウイルス-neutralising antibodies.
Plasma 見本s from all of them were first 実験（する）d for neutralising activity against the ウイルス, and saw a 広範囲にわたって 変化させるing 範囲 of neutralising antibodies.
Five 患者s were 焦点（を合わせる）d on because their plasma ウイルス-neutralising titers were の中で the highest.
その上の 熟考する／考慮するs in other animals and people are 存在 planned.
